



**November 7, 2018**

**VIA UPS EXPRESS**

Victor A. Poteet, PharmD., CEO  
Compounding Pharmacy of America, Inc.  
6216 Highland Place Way  
Suite 201-B  
Knoxville, TN 37919-4068

Dr. Poteet:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Compounding Pharmacy of America, Inc., located at 6216 Highland Place Way, Suite 201-B, Knoxville, TN 37919-4068, from January 23, 2018, to February 1, 2018, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the Tennessee State Board of Pharmacy for follow up.

When the Agency considers an inspection to be "closed" under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Rebecca Asente, Compliance Officer, by email at [Rebecca.asente@fda.hhs.gov](mailto:Rebecca.asente@fda.hhs.gov) or by phone at 504-846-6104.

Sincerely,

John W. Diehl -  
S3

Digitally signed by John W. Diehl -S3  
DN: c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People, cn=John W. Diehl -S3,  
0.9.2342.19200300.100.1.1=2000099727  
Date: 2018.11.07 16:05:25 -0600

LCDR John W. Diehl, M.S.  
Director, Compliance Branch  
Office of Pharmaceutical Quality Operations,  
Division II

U.S. Food & Drug Administration  
Office of Pharmaceutical Quality Operations, Division II  
4040 N. Central Expressway, Suite 300  
Dallas, Texas 75204  
[www.fda.gov](http://www.fda.gov)